(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Canaan, ANSYS, and Canopy Growth.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Canaan (CAN) | 3.17 | 22.87% | 2023-12-25 12:15:48 |
| 2 | ANSYS (ANSS) | 357.98 | 18.08% | 2023-12-25 12:10:39 |
| 3 | Canopy Growth (CGC) | 5.14 | 13.97% | 2023-12-25 12:23:07 |
| 4 | Cara Therapeutics (CARA) | 0.67 | 12.27% | 2023-12-24 19:44:05 |
| 5 | Altair Engineering (ALTR) | 83.29 | 11.48% | 2023-12-25 12:10:28 |
| 6 | FibroGen (FGEN) | 0.76 | 8.79% | 2023-12-25 08:12:07 |
| 7 | Curis (CRIS) | 13.78 | 8.59% | 2023-12-25 07:42:06 |
| 8 | Inovio Pharmaceuticals (INO) | 0.44 | 8.29% | 2023-12-25 12:12:58 |
| 9 | Broadwind (BWEN) | 2.83 | 8.02% | 2023-12-24 19:06:05 |
| 10 | Tilray (TLRY) | 2.19 | 7.88% | 2023-12-25 12:17:14 |
The three biggest losers today are Cyclacel Pharmaceuticals, NetEase, and Nike.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Cyclacel Pharmaceuticals (CYCC) | 2.74 | -23.89% | 2023-12-25 11:08:06 |
| 2 | NetEase (NTES) | 87.64 | -16.07% | 2023-12-25 12:13:48 |
| 3 | Nike (NKE) | 108.04 | -11.83% | 2023-12-25 12:59:53 |
| 4 | Aspen Group (ASPU) | 0.15 | -8.1% | 2023-12-25 12:15:36 |
| 5 | Synopsys (SNPS) | 524.46 | -6.34% | 2023-12-25 12:51:18 |
| 6 | Dawson Geophysical Company (DWSN) | 1.70 | -6.08% | 2023-12-25 15:46:06 |
| 7 | China Jo-Jo Drugstores (CJJD) | 0.19 | -5.75% | 2023-12-25 03:11:05 |
| 8 | Groupon (GRPN) | 12.11 | -4.95% | 2023-12-25 12:12:38 |
| 9 | Bilibili (BILI) | 11.00 | -4.93% | 2023-12-25 12:51:51 |
| 10 | Super Micro Computer (SMCI) | 289.72 | -4.75% | 2023-12-25 12:14:36 |
Winners today
1. Canaan (CAN) – 22.87%
Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.
NASDAQ ended the session with Canaan jumping 22.87% to $3.17 on Tuesday, after five consecutive sessions in a row of gains. NASDAQ rose 0.19% to $14,992.97, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Canaan has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.
More news about Canaan.
2. ANSYS (ANSS) – 18.08%
ANSYS, Inc. develops and markets engineering simulation software and services worldwide. It offers ANSYS Workbench, a framework upon which its multiphysics engineering simulation technologies are built and enables engineers to simulate the interactions between structures, heat transfer, fluids, electronics, and optical elements in a unified engineering simulation environment; high-performance computing product suite and the cloud; power analysis and optimization software suite that manages the power budget, power delivery integrity, and power-induced noise in an electronic design; and structural analysis product suite that provides simulation tools for product design and optimization. The company also provides electronics product suite that offers electromagnetic field simulation software for designing electronic and electromechanical products; SCADE product suite, a solution for embedded software simulation, code production, and automated certification; fluids product suite that enables modeling of fluid flow and other related physical phenomena; Ansys Granta products to give access to material intelligence; photonic design and simulation tools; and optical sensor and closed-loop, and real-time simulation, as well as safety-certified embedded software solutions. In addition, the company provides Discovery product family for use in the simulation of product design; and academic product suite used in research and teaching settings, which allows students to become familiar with its simulation software. It serves engineers, designers, researchers, and students in the aerospace and defense, automotive, construction, consumer products, energy, healthcare, high-tech, industrial equipment, and materials and chemical processing industries. ANSYS, Inc. was founded in 1970 and is headquartered in Canonsburg, Pennsylvania.
NASDAQ ended the session with ANSYS jumping 18.08% to $357.98 on Tuesday while NASDAQ rose 0.19% to $14,992.97.
Earnings Per Share
As for profitability, ANSYS has a trailing twelve months EPS of $5.51.
PE Ratio
ANSYS has a trailing twelve months price to earnings ratio of 64.97. Meaning, the purchaser of the share is investing $64.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.13%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.9%, now sitting on 2.16B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 20.7% and 2.2%, respectively.
Sales Growth
ANSYS’s sales growth is 15.5% for the ongoing quarter and 7.2% for the next.
More news about ANSYS.
3. Canopy Growth (CGC) – 13.97%
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
NASDAQ ended the session with Canopy Growth jumping 13.97% to $5.14 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.88.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.66%.
More news about Canopy Growth.
4. Cara Therapeutics (CARA) – 12.27%
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
NASDAQ ended the session with Cara Therapeutics jumping 12.27% to $0.67 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.19% to $14,992.97, after two sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Cara Therapeutics has a trailing twelve months EPS of $-2.15.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -86.16%.
More news about Cara Therapeutics.
5. Altair Engineering (ALTR) – 11.48%
Altair Engineering Inc., together with its subsidiaries, provides software and cloud solutions in the areas of simulation, high-performance computing, data analytics, and artificial intelligence in the United States and internationally. The company operates in two segments: Software and Client Engineering Services. The Software segment offers solvers and optimization technology products, high-performance computing software applications and hardware products, modeling and visualization tools, data analytics and analysis products, and Internet of Things platform and analytics tools, as well as support and the complementary software products. This segment also provides software technologies in the areas of computational fluid dynamics and fatigue, manufacturing process simulation, and cost estimation for the applications in marine, motorcycle, aerospace, chemical, and architecture industries; and software-related services, such as consulting, implementation, and training services that focuses on the product design and development expertise and analysis from the component level up to complete product engineering at various stage of the lifecycle. The Client Engineering Services segment provides client engineering services. In addition, the company is involved in the development and sale of solid state lighting technology along with communication and control protocols based on its intellectual property for the direct replacement of fluorescent light tubes with LED lamps. Its integrated suite of software optimizes design performance across various disciplines, including structures, motion, fluids, thermal management, electromagnetics, system modeling, and embedded systems. The company serves universities, government agencies, manufacturers, pharmaceutical firms, banking, financial services, and insurance, weather prediction agencies, and electronics design companies. Altair Engineering Inc. was incorporated in 1985 and is headquartered in Troy, Michigan.
NASDAQ ended the session with Altair Engineering rising 11.48% to $83.29 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Altair Engineering has a trailing twelve months EPS of $-0.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.83%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Altair Engineering’s EBITDA is 11.15.
More news about Altair Engineering.
6. FibroGen (FGEN) – 8.79%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen rising 8.79% to $0.76 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be oversold (<=20).
Moving Average
FibroGen’s value is way higher than its 50-day moving average of $0.56 and way below its 200-day moving average of $7.34.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $0.76 at 01:32 EST, way under its 52-week high of $25.69 and way above its 52-week low of $0.33.
Revenue Growth
Year-on-year quarterly revenue growth grew by 155.1%, now sitting on 154.98M for the twelve trailing months.
More news about FibroGen.
7. Curis (CRIS) – 8.59%
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
NASDAQ ended the session with Curis rising 8.59% to $13.78 on Tuesday while NASDAQ rose 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Curis has a trailing twelve months EPS of $-9.34.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -110.22%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.3%, now sitting on 10.21M for the twelve trailing months.
More news about Curis.
8. Inovio Pharmaceuticals (INO) – 8.29%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals rising 8.29% to $0.44 on Tuesday while NASDAQ rose 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.63.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.3%.
Volume
Today’s last reported volume for Inovio Pharmaceuticals is 3787490 which is 9.96% above its average volume of 3444400.
Revenue Growth
Year-on-year quarterly revenue growth declined by 95.8%, now sitting on 854.02k for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Inovio Pharmaceuticals’s EBITDA is -19.28.
Yearly Top and Bottom Value
Inovio Pharmaceuticals’s stock is valued at $0.44 at 01:32 EST, way below its 52-week high of $1.99 and way higher than its 52-week low of $0.32.
More news about Inovio Pharmaceuticals.
9. Broadwind (BWEN) – 8.02%
Broadwind, Inc. manufactures and sells structures, equipment, and components for clean tech and other specialized applications primarily in the United States. It operates through three segments: Heavy Fabrications, Gearing, and Industrial Solutions. The Heavy Fabrications segment provides fabrications to various industrial markets. It offers steel towers and adapters primarily to wind turbine manufacturers. The Gearing segment provides gearing, and gearboxes and systems for onshore and offshore oil and gas fracking and drilling, surface and underground mining, wind energy, steel, material handling, and other infrastructure markets. This segment also offers heat treat services for aftermarket and original equipment manufacturer applications. The Industrial Solutions segment provides supply chain solutions for offering instrumentation and controls, valve assemblies, sensor devices, fuel system components, electrical junction boxes and wiring, energy storage services, and electromechanical devices; light fabrication, inventory management, and kitting and assembly services; packaging solutions; and fabricating services for panels and sub-assemblies to combined cycle natural gas turbine market. The company sells its products to the energy, mining, and infrastructure sector customers through its direct sales force and independent sales agents. The company was formerly known as Broadwind Energy, Inc. and changed its name to Broadwind, Inc. in May 2020. Broadwind, Inc. is headquartered in Cicero, Illinois.
NASDAQ ended the session with Broadwind rising 8.02% to $2.83 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.19% to $14,992.97, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Broadwind has a trailing twelve months EPS of $0.17.
PE Ratio
Broadwind has a trailing twelve months price to earnings ratio of 16.65. Meaning, the purchaser of the share is investing $16.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.24%.
Moving Average
Broadwind’s worth is way above its 50-day moving average of $2.51 and way under its 200-day moving average of $3.55.
Volume
Today’s last reported volume for Broadwind is 123074 which is 27.67% below its average volume of 170164.
Yearly Top and Bottom Value
Broadwind’s stock is valued at $2.83 at 01:32 EST, way below its 52-week high of $6.10 and way higher than its 52-week low of $1.66.
More news about Broadwind.
10. Tilray (TLRY) – 7.88%
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
NASDAQ ended the session with Tilray jumping 7.88% to $2.19 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Tilray has a trailing twelve months EPS of $-2.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.99%.
Volatility
Tilray’s last week, last month’s, and last quarter’s current intraday variation average was 2.55%, 1.08%, and 3.55%.
Tilray’s highest amplitude of average volatility was 3.67% (last week), 4.07% (last month), and 3.55% (last quarter).
More news about Tilray.
Losers Today
1. Cyclacel Pharmaceuticals (CYCC) – -23.89%
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
NASDAQ ended the session with Cyclacel Pharmaceuticals dropping 23.89% to $2.74 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Cyclacel Pharmaceuticals has a trailing twelve months EPS of $-29.85.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -187.4%.
Yearly Top and Bottom Value
Cyclacel Pharmaceuticals’s stock is valued at $2.74 at 01:32 EST, way under its 52-week high of $17.55 and way above its 52-week low of $2.20.
Volume
Today’s last reported volume for Cyclacel Pharmaceuticals is 220058 which is 653.98% above its average volume of 29186.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 21.4% and 16%, respectively.
More news about Cyclacel Pharmaceuticals.
2. NetEase (NTES) – -16.07%
NetEase, Inc. engages in online games, music streaming, online intelligent learning services, and internet content services businesses in China and internationally . The company operates through Games and Related Value-Added Services, Youdao, Cloud Music, and Innovative Businesses and Others segments. It develops and operates PC and mobile games, as well as offers games licensed from other game developers. The company's products and services include Youdao Dictionary, an online knowledge tool; Youdao Translation, a tool specifically designed to support translation needs of business and leisure travelers; U-Dictionary, an online dictionary and translation app; Youdao Kids' Dictionary, a smart and fun tool; smart devices, such as Youdao Dictionary Pen, Youdao Smart Learning Pad, Youdao Listening Pod, Youdao Smart Light, Youdao Pocket Translator, and Youdao Super Dictionary; online courses; interactive learning apps; and education digitalization solutions, such as Youdao Smart Learning Terminal, a device that automates paper-based homework processing; Youdao Smart Cloud, a cloud-based platform that allows third-party app developers, smart device brands, and manufacturers to the company's OCR capabilities; and Youdao Sports, a sports-centric educational system. Its products and services also include NetEase Cloud Music, a music streaming platform; Yanxuan, an e-commerce platform, which sells private label products; www.163.com portal and related mobile app, Wangyi Xinwen, which deliver information such as news, sports events, technology, fashion trends, and online entertainment; NetEase Mail, an email service; NetEase CC Live streaming, a live streaming platform with a focus on game broadcasting; and NetEase Pay, a payment platform. The company was formerly known as NetEase.com, Inc. and changed its name to NetEase, Inc. in March 2012. NetEase, Inc. was founded in 1997 and is headquartered in Hangzhou, the People's Republic of China.
NASDAQ ended the session with NetEase sliding 16.07% to $87.64 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.19% to $14,992.97, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, NetEase has a trailing twelve months EPS of $5.77.
PE Ratio
NetEase has a trailing twelve months price to earnings ratio of 15.19. Meaning, the purchaser of the share is investing $15.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.68%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 1.76 and the estimated forward annual dividend yield is 2%.
Moving Average
NetEase’s value is way under its 50-day moving average of $108.11 and way under its 200-day moving average of $98.89.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 61.7% and 8.6%, respectively.
Sales Growth
NetEase’s sales growth for the current quarter is 8%.
More news about NetEase.
3. Nike (NKE) – -11.83%
NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, accessories, and services worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. It also sells a line of performance equipment and accessories comprising bags, sport balls, socks, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. In addition, the company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel; and licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. It sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.
NYSE ended the session with Nike falling 11.83% to $108.04 on Tuesday, following the last session’s downward trend. NYSE jumped 0.27% to $16,770.45, after two successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Nike has a trailing twelve months EPS of $3.42.
PE Ratio
Nike has a trailing twelve months price to earnings ratio of 31.59. Meaning, the purchaser of the share is investing $31.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.03%.
Volatility
Nike’s last week, last month’s, and last quarter’s current intraday variation average was 0.38%, 0.69%, and 1.22%.
Nike’s highest amplitude of average volatility was 1.05% (last week), 0.97% (last month), and 1.22% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Nike’s EBITDA is 3.23.
More news about Nike.
4. Aspen Group (ASPU) – -8.1%
Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.
NASDAQ ended the session with Aspen Group dropping 8.1% to $0.15 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.
More news about Aspen Group.
5. Synopsys (SNPS) – -6.34%
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.
NASDAQ ended the session with Synopsys sliding 6.34% to $524.46 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $7.92.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 66.22. Meaning, the purchaser of the share is investing $66.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.75%.
Moving Average
Synopsys’s value is above its 50-day moving average of $517.47 and way above its 200-day moving average of $446.32.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.5%, now sitting on 5.84B for the twelve trailing months.
More news about Synopsys.
6. Dawson Geophysical Company (DWSN) – -6.08%
Dawson Geophysical Company provides onshore seismic data acquisition and processing services in the United States and Canada. The company acquires and processes 2-D, 3-D, and multi-component seismic data for its clients, including oil and gas companies, and independent oil and gas operators, as well as providers of multi-client data libraries. Its seismic crews supply seismic data primarily to companies engaged in the exploration and development of oil and natural gas on land and in land-to-water transition areas. The company also serves the potash mining industry. Dawson Geophysical Company was founded in 1952 and is headquartered in Midland, Texas. Dawson Geophysical Company is a subsidiary of Wilks Brothers, LLC.
NASDAQ ended the session with Dawson Geophysical Company falling 6.08% to $1.70 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ rose 0.19% to $14,992.97, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Dawson Geophysical Company has a trailing twelve months EPS of $-0.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.91%.
More news about Dawson Geophysical Company.
7. China Jo-Jo Drugstores (CJJD) – -5.75%
China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2021, it had 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.
NASDAQ ended the session with China Jo-Jo Drugstores falling 5.75% to $0.19 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, China Jo-Jo Drugstores has a trailing twelve months EPS of $-2.07.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.29%.
Volume
Today’s last reported volume for China Jo-Jo Drugstores is 246353 which is 11.4% below its average volume of 278057.
Moving Average
China Jo-Jo Drugstores’s value is way under its 50-day moving average of $0.21 and way below its 200-day moving average of $0.88.
Yearly Top and Bottom Value
China Jo-Jo Drugstores’s stock is valued at $0.19 at 01:32 EST, way under its 52-week high of $9.65 and way above its 52-week low of $0.17.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.4%, now sitting on 148.81M for the twelve trailing months.
More news about China Jo-Jo Drugstores.
8. Groupon (GRPN) – -4.95%
Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Groupon falling 4.95% to $12.11 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Groupon has a trailing twelve months EPS of $-4.5.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -567.07%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 12.4%, now sitting on 525.35M for the twelve trailing months.
Sales Growth
Groupon’s sales growth is negative 9.4% for the ongoing quarter and negative 2.1% for the next.
More news about Groupon.
9. Bilibili (BILI) – -4.93%
Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
NASDAQ ended the session with Bilibili sliding 4.93% to $11.00 on Tuesday while NASDAQ rose 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Bilibili has a trailing twelve months EPS of $-1.72.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.31%.
Moving Average
Bilibili’s worth is way under its 50-day moving average of $13.05 and way under its 200-day moving average of $16.28.
More news about Bilibili.
10. Super Micro Computer (SMCI) – -4.75%
Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States, Europe, Asia, and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. The company provides application-optimized server solutions, rackmount and blade servers, storage, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and technical documentation, and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. The company was incorporated in 1993 and is headquartered in San Jose, California.
NASDAQ ended the session with Super Micro Computer falling 4.75% to $289.72 on Tuesday while NASDAQ jumped 0.19% to $14,992.97.
Earnings Per Share
As for profitability, Super Micro Computer has a trailing twelve months EPS of $10.84.
PE Ratio
Super Micro Computer has a trailing twelve months price to earnings ratio of 26.73. Meaning, the purchaser of the share is investing $26.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.32%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 7.39B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Super Micro Computer’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for Super Micro Computer is 4439500 which is 36.6% above its average volume of 3249850.
Moving Average
Super Micro Computer’s value is above its 50-day moving average of $273.56 and way above its 200-day moving average of $229.42.
More news about Super Micro Computer.
Stay up to date with our winners and losers daily report
